Related Experiment Videos
Acromegaly: a new therapy
1Pharmacia Corp, Peapack, NJ 07977, USA. Keith.Friend@pharmacia.com
Summary
Pegvisomant therapy effectively normalizes serum insulin-like growth factor I (IGF-I) in most acromegaly patients, even those resistant to other treatments. This growth hormone receptor antagonist offers a safe and promising new option.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Acromegaly treatment is challenging, with many patients failing to normalize serum insulin-like growth factor I (IGF-I) despite standard therapies.
- Current treatments include surgery, radiation, dopamine agonists, and somatostatin analogs.
Purpose of the Study:
- To review the characteristics and indications of pegvisomant therapy for acromegaly.
- To compare pegvisomant, a growth hormone (GH) receptor antagonist, with existing pharmacological treatments.
Main Methods:
- Discussion of pegvisomant's clinical profile.
- Comparison of pegvisomant with somatostatin and dopamine agonists.
Main Results:
- Pegvisomant normalizes serum IGF-I in up to 97% of acromegaly patients, including those refractory to other treatments.
- Treatment with pegvisomant leads to a rapid, non-progressive increase in circulating GH levels.
- The drug is well-tolerated and safe in clinical studies.
Conclusions:
- Pegvisomant demonstrates significant efficacy in treating acromegaly.
- This novel GH receptor antagonist represents a potentially important therapeutic option for acromegaly patients.
- Further research into pegvisomant's mechanism of action and long-term effects is warranted.